The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

For new and old investors, taking full advantage of the stock market and investing with confidence are common goals. Zacks Premium provides lots of different ways to do both. The research service ...

Senseonics SENS recently announced the full availability of its long-term, implantable Continuous Glucose Monitoring (CGM) ...

Meet Actress Anitaka Knight, a fierce advocate for health awareness and unique self-expression in the Black community.

New CEO Jake Leach said the company plans a trial readout in mid-2026 to support coverage of its glucose sensors in Type 2 users who don’t take insulin.

DexCom expects 2026 total revenue to be in a range of $5.16 billion to $5.25 billion, representing growth of 11% to 13% for the year. Sylvain indicated, "This guidance assumes continued strong ...

Dexcom (NSDQ:DXCM) shares ticked up after hours today on fourth-quarter results that came in ahead of the consensus forecast.

(DXCM) on Thursday reported fourth-quarter earnings of $267.3 million. On a per-share basis, the San Diego-based company said it had profit of 68 cents.

Dexcom announced a new wave of AI-powered features designed to help users understand how food and daily habits affect their metabolic health.

DexCom recently reported preliminary, unaudited results showing fourth-quarter 2025 revenue of about US$1.26 billion and full-year 2025 revenue of roughly US$4.66 billion, both rising at double-digit ...

Dexcom’s new CEO is eyeing growth in the international market as a key strategy for 2026, fresh off the back of the company reporting strong full year 2025 (FY25) revenues. Speaking at the ongoing J.P ...

Sourced from the diabetes community at large through an open call earlier this year, the 16 selected advocates represent strength, advocacy and pride in living with Type 1, Type 2 and prediabetes ...